College of Pharmacy


  • J. Wang, J. Zhang, N. T. D. Nguyen, Y. Chen, J. Hsieh, and X. Dong*. Quantitative Measurements of IR780 in Formulations and Tissues. Journal of Pharmaceutical and Biomedical Analysis. (impact factor: 3.2) 
  • S. Le, C. Chang, T. Nguyen, Y. Liu, Y. Chen, E. Hernandez, P. Kapur, J. Hsieh, K. Johnston, and X. Dong*. Anticancer efficacy of oral docetaxel nanoformulation for metronomic chemotherapy in metastatic lung cancer. Journal of Biomedical Nanotechnology. 16 (5): 583-593 (2020). doi:10.1166/jbn.2020.2925 (impact factor: 4.4) 
  • I. Tanaudommongkon, A. Tanaudommongkon, P. Prathipati, J. Nguyen, E. T. Keller and X. Dong*. Curcumin nanoparticles and their cytotoxicity in docetaxel-resistant castration-resistant prostate cancer cells. Biomedicines. 8 (253) (2020). doi:10.3390/biomedicines8080253 (impact factor: 4.7) 
  • X. Dong*. Current strategies for brain drug delivery. Theranostics. 8(6): 1481-1493 (2018). doi: 10.7150/thno.21254. (Invited review paper) (impact factor: 8.6) 
  • P. Prathipati, J. Zhu and X. Dong*. Development of novel HDL-mimicking a-tocopherol-coated nanoparticles to encapsulate nerve growth factor and evaluation of biodistribution. European Journal of Pharmaceutics and Biopharmaceutics. 108, 126-135 (2016). doi: 10.1016/j.ejpb.2016.08.005 (impact factor: 4.3) 
  • K. Pham, D. Li, S. Guo, S. Penzak and X. Dong*. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles. Journal of Controlled Release. 226, 88-97 (2016). doi:10.1016/j.jconrel.2016.02.001 (impact factor: 7.7) 
  • S. Guo, K. Pham, D. Li, S. Penzak and X. Dong*. Novel in situ self-assembly nanoparticles for formulating a poorly water-soluble drug in oral solid granules improving stability, palatability and bioavailability. International Journal of Nanomedicine. 11, 1451-1460 (2016). (impact factor: 4.4) 
  • X. Dong and R.J. Mumper. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine. 5(4), 597-615 (2010). (Invited review paper) (impact factor: 4.7) 
  • X. Dong, C.A. Mattingly, M. Tseng, M. Cho, Y. Liu, V. Adams and R.J. Mumper. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Research. 69, 3918-26 (2009). (impact factor: 9.7) 
  • X. Dong, C.A. Mattingly, M. Tseng, M. Cho, V. Adams and R.J. Mumper. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. European Journal of Pharmaceutics and Biopharmaceutics. 72, 9-17 (2008). (impact factor: 4.3)